-
1.发明授权(R)-(Z)-1-azabicyclo [2.2.1] heptan-3-one,O-[3-(3-methoxyphenyl)-2-propynyl] oxime maleate as a pharmaceutical agent 失效（R） - （Z）-1-氮杂双环[2.2.1]庚-3-酮，O- [3-（3-甲氧基苯基）-2-丙炔基]肟
公开(公告)号：US5534522A
公开(公告)日：1996-07-09
申请号：US474622
申请日：1995-06-07
IPC分类号： A61K31/40 , A61P25/02 , A61P25/04 , A61P25/28 , C07D487/08 , A61K31/445
CPC分类号： C07D487/08
摘要： The [1:1] maleate salt of [R-(Z)]-1-Azabicyclo [2.2.1]heptan-3-one, O-[3-(3-methoxyphenyl)-2-propynyl]-oxime, a known muscarinic agonist has unique properties relative to other salts of the compound, rendering it a desirable pharmaceutical.
摘要翻译： [R-（Z）] -1-氮杂双环[2.2.1]庚-3-酮的[1：1]马来酸盐，O- [3-（3-甲氧基苯基）-2-丙炔基] - 肟 已知的毒蕈碱激动剂相对于化合物的其它盐具有独特的性质，使其成为期望的药物。
-
2.发明授权Azabicyclo and azacyclo oxime and amine cholinergic agents and methods of treatment 失效氮杂双环和吖嗪肟和胺类胆碱能药剂及治疗方法
公开(公告)号：US5346911A
公开(公告)日：1994-09-13
申请号：US110904
申请日：1993-08-24
申请人： Corinne E. Augelli-Szafran , Stephen D. Barrett , Bradley W. Caprathe , Adam A. Galan , Juan C. Jaen , David J. Lauffer , Walter H. Moos , Michael R. Pavia , Kathryn B. Sanders , Haile Tecle , Anthony J. Thomas
发明人： Corinne E. Augelli-Szafran , Stephen D. Barrett , Bradley W. Caprathe , Adam A. Galan , Juan C. Jaen , David J. Lauffer , Walter H. Moos , Michael R. Pavia , Kathryn B. Sanders , Haile Tecle , Anthony J. Thomas
IPC分类号： C07D211/72 , C07D451/04 , C07D453/02 , C07D487/08 , A61K31/44 , C07D211/70
CPC分类号： C07D211/72 , C07D451/04 , C07D453/02 , C07D487/08
摘要： Pharmaceutically useful nitrogen containing cyclic oxime and amine substituted compounds which are azabicyclo[2.2.1]oximes, azabicyclo[2.2.2]oximes, azabicyclo[2.2.1]amines, azabicyclo[2.2.2]amines, azabicyclo[3.2.1]oximes, and amine containing heterocyclic oximes wherein the heterocyclic ring contains from 3 to 7 carbon atoms are disclosed.
摘要翻译： 含有偶氮二环[2.2.1]肟，氮杂双环[2.2.2]肟，氮杂双环[2.2.1]胺，氮杂双环[2.2.2]胺，氮杂双环[3.2.1] 肟和含有杂环肟的胺，其中杂环含有3至7个碳原子。
-
公开(公告)号：US08455512B2
公开(公告)日：2013-06-04
申请号：US13112520
申请日：2011-05-20
申请人： Stephen D. Barrett , James B. Kramer , Mark L. Boys , Huifen Chen
发明人： Stephen D. Barrett , James B. Kramer , Mark L. Boys , Huifen Chen
IPC分类号： A61K31/4365 , C07D495/04
CPC分类号： C07D495/04 , A61K9/0014 , A61K31/4365
摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有在本说明书中定义的任何值及其药学上可接受的盐， 可用作治疗TGFbeta介导的病症（包括癌症和纤维化疾病）的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。
-
公开(公告)号：US20140031385A1
公开(公告)日：2014-01-30
申请号：US13864457
申请日：2013-04-17
申请人： Stephen D. Barrett , James B. Kramer , Mark L. Boys , Huifen Chen
发明人： Stephen D. Barrett , James B. Kramer , Mark L. Boys , Huifen Chen
IPC分类号： C07D495/04
CPC分类号： C07D495/04 , A61K9/0014 , A61K31/4365
摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐， 可用作治疗TGFbeta介导的病症（包括癌症和纤维化疾病）的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。
-
公开(公告)号：US07964612B2
公开(公告)日：2011-06-21
申请号：US11871311
申请日：2007-10-12
申请人： Stephen D. Barrett , James B. Kramer , Mark L Boys , Huifen Chen
发明人： Stephen D. Barrett , James B. Kramer , Mark L Boys , Huifen Chen
IPC分类号： A61K31/4365 , C07D495/04
CPC分类号： C07D495/04 , A61K9/0014 , A61K31/4365
摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐， 可用作治疗TGF-bgr介导的病症，包括癌症和纤维化疾病的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。
-
6.发明申请PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS 有权PROSTAGLANDIN E1和E2模拟物治疗各种医疗条件公开(公告)号：US20090221654A1
公开(公告)日：2009-09-03
申请号：US12271764
申请日：2008-11-14
申请人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andrei M. Kornilov , Kirk M. Maxey , Adam Uzieblo
发明人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andrei M. Kornilov , Kirk M. Maxey , Adam Uzieblo
IPC分类号： A61K31/428 , C07D333/52 , A61K31/381 , A61K31/19 , C07C59/00 , C07D277/62
CPC分类号： C07C405/00
摘要： A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
摘要翻译： 具有对EP受体的选择性并表现出EP激动剂活性的前列腺素类似物，其可用于扩展造血干细胞群体或治疗或预防流感，骨折，骨病，青光眼，眼高血压，痛经，早产，免疫功能障碍 ，骨质疏松症，哮喘，过敏，男性性功能障碍，女性性功能障碍，牙周病，胃溃疡，肾脏疾病或其他EP受体介导的病症。
-
公开(公告)号：US08901319B2
公开(公告)日：2014-12-02
申请号：US13500254
申请日：2009-10-16
IPC分类号： C07D405/00 , C07D307/935
CPC分类号： C07D307/935
摘要： A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.
摘要翻译： 用于合成和纯化用于制备F系列前列腺素化合物和合成中间体的方法。 合成中间体是固体，可以通过沉淀来纯化，因此可以以高纯度形式形成代表性的F系列前列腺素化合物，如拉坦前列素，比马前列素，泼尼松龙，氯哌醇和其取代的类似物。
-
公开(公告)号：US20120283451A1
公开(公告)日：2012-11-08
申请号：US13500254
申请日：2009-10-16
IPC分类号： C07C405/00 , C07D307/935
CPC分类号： C07D307/935
摘要： A process for the synthesis and purification of F-series prostaglandin compounds and synthetic intermediates used to prepare them. The synthetic intermediates are solid and may be purified by precipitation and therefore may form the representative F-series prostaglandin compounds such as latanoprost, bimatoprost, fluprostenol, cloprostenol, and substituted analogs therefrom in highly pure forms.
摘要翻译： 用于合成和纯化用于制备F系列前列腺素化合物和合成中间体的方法。 合成中间体是固体，可以通过沉淀来纯化，因此可以以高纯度形式形成代表性的F系列前列腺素化合物，如拉坦前列素，比马前列素，泼尼松龙，氯哌醇和其取代的类似物。
-
公开(公告)号：US20110224251A1
公开(公告)日：2011-09-15
申请号：US13112520
申请日：2011-05-20
申请人： Stephen D. Barrett , Mark L. Boys , Huifen Chen , James B. Kramer
发明人： Stephen D. Barrett , Mark L. Boys , Huifen Chen , James B. Kramer
IPC分类号： A61K31/4365 , C07D495/04 , A61P17/02 , A61P35/00 , A61P13/12 , A61P43/00 , A61P1/16 , A61P11/00 , A61P9/00 , A61P17/00
CPC分类号： C07D495/04 , A61K9/0014 , A61K31/4365
摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有本说明书中定义的任何值及其药学上可接受的盐， 可用作治疗TGF-bgr介导的病症，包括癌症和纤维化疾病的治疗剂。 还提供了包含一种或多种式I化合物的药物组合物。
-
10.发明授权Prostaglandin E1 and E2 analogs for the treatment of various medical conditions 有权前列腺素E1和E2类似物用于治疗各种医疗条件公开(公告)号：US08063240B2
公开(公告)日：2011-11-22
申请号：US12271764
申请日：2008-11-14
申请人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andriy M. Kornilov , Kirk M. Maxey , Adam Uzieblo
发明人： Nancy S. Barta , Stephen D. Barrett , Gregory W. Endres , Andriy M. Kornilov , Kirk M. Maxey , Adam Uzieblo
CPC分类号： C07C405/00
摘要： A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular hypertension, dysmenorrhoea, pre-term labor, immune disorders, osteoporosis, asthma, allergy, male sexual dysfunction, female sexual dysfunction, periodontal disease, gastric ulcer, renal disease, or other EP receptor-mediated conditions.
摘要翻译： 具有对EP受体的选择性并表现出EP激动剂活性的前列腺素类似物，其可用于扩展造血干细胞群体或治疗或预防流感，骨折，骨病，青光眼，眼高血压，痛经，早产，免疫功能障碍 ，骨质疏松症，哮喘，过敏，男性性功能障碍，女性性功能障碍，牙周病，胃溃疡，肾脏疾病或其他EP受体介导的病症。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.034 秒)
